FDA Accepts Marketing Application for Churchill’s Yonsa Microsize Tablets for Advanced Prostate Cancer

FDA Accepts Marketing Application for Churchill’s Yonsa Microsize Tablets for Advanced Prostate Cancer
The U.S. Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) for Yonsa (abiraterone acetate) ultramicrosize tablets for the treatment of castration resistant prostate cancer that has spread outside the prostate, according to the drug’s developer, Churchill Pharmaceuticals. The FDA has until March 19, 2018, to review the NDA under the Prescription Drug

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *